83196-67-2Relevant academic research and scientific papers
The antimalarial drug amodiaquine stabilizes p53 through ribosome biogenesis stress, independently of its autophagy-inhibitory activity
Espinoza, Jaime A.,Zisi, Asimina,Kanellis, Dimitris C.,Carreras-Puigvert, Jordi,Henriksson, Martin,Hühn, Daniela,Watanabe, Kenji,Helleday, Thomas,Lindstr?m, Mikael S.,Bartek, Jiri
, p. 773 - 789 (2019/07/18)
Pharmacological inhibition of ribosome biogenesis is a promising avenue for cancer therapy. Herein, we report a novel activity of the FDA-approved antimalarial drug amodiaquine which inhibits rRNA transcription, a rate-limiting step for ribosome biogenesi
Synthesis and antimalarial activity of new analogues of amodiaquine
Delarue-Cochin, Sandrine,Paunescu, Emilia,Maes, Louis,Mouray, Elisabeth,Sergheraert, Christian,Grellier, Philippe,Melnyk, Patricia
, p. 252 - 260 (2008/09/18)
In order to determine the real significance of the 4′-phenolic group in the antimalarial activity and/or cytotoxicity of amodiaquine (AQ), analogues for which this functionality was shifted or modified were synthesized. Good in vitro antimalarial activity
